Rocket Pharmaceuticals in-27RCKTWPreferred / convertible
13F holders, Q3 2025 (September 30)11holders −1
1new positions
2sold out
1famous investor
$0.10avg. 13F price*
At the end of Q3 2025, 11 institutions reported holding Rocket Pharmaceuticals in-27 (RCKTW) in their 13F filings, down 1 from Q2 2025. 1 opened new positions and 2 sold out. The largest holders were Boothbay Fund Management, LLC ($120K), Walleye Capital LLC ($23K) and Sio Capital Management, LLC ($14K). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Rocket Pharmaceuticals in-27
- CUSIP
- 77313F114
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $50 |
| Exits | 2 | $2K |
All 13F filers, Q2 2025 → Q3 2025: 6,407 shares bought and 126,062 shares sold, net −119,655 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Boothbay Fund Management, LLC | — | No change | 36,912 | $120K |
| Walleye Capital LLC | — | Reduce -7.7% | 593,631 | $23K |
| Sio Capital Management, LLC | — | No change | 400,000 | $14K |
| RTW Investments, LP | — | No change | 350,000 | $14K |
| Citadel Advisors | — | Reduce -0.7% | 312,789 | $11K |
| Silverarc Capital Management, LLC | — | No change | 104,828 | $4K |
| Affinity Asset Advisors, LLC | — | No change | 75,000 | $3K |
| LMR Partners LLP | — | No change | 75,731 | $3K |
| Susquehanna International Group, LLP | — | Add +12.1% | 47,692 | $2K |
| Ancora Advisors LLC | — | No change | 6,000 | $235 |
| UBS Group AG | — | New | 1,274 | $50 |
"% of holder's portfolio" is RCKTW's weight in each manager's 13F, not the share of Rocket Pharmaceuticals in-27 the manager owns.